Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have earned a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and one has given a strong buy rating to the company. Aeglea Bio Therapeutics’ rating score has declined by 50% from 90 days ago as a result of various analysts’ ratings changes.
Brokers have set a 1-year consensus price target of $18.00 for the company and are forecasting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 189 out of 265 based on the ratings given to its competitors.
Several equities analysts recently issued reports on AGLE shares. Needham & Company LLC raised their price target on Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, March 14th. Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $18.00 price target on shares of Aeglea Bio Therapeutics in a report on Wednesday, March 14th.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC boosted its holdings in Aeglea Bio Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after buying an additional 8,372 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Aeglea Bio Therapeutics by 150.8% during the fourth quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after buying an additional 19,300 shares during the last quarter. Hedge funds and other institutional investors own 47.43% of the company’s stock.
Aeglea Bio Therapeutics stock opened at $10.64 on Friday. The stock has a market capitalization of $177.86, a PE ratio of -5.91 and a beta of 1.38. Aeglea Bio Therapeutics has a 1-year low of $2.81 and a 1-year high of $10.97.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/19/analysts-set-18-00-price-target-for-aeglea-bio-therapeutics-inc-agle.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.